EUVIMEDEUVIMED entdecken
Crossref

The role of SBRT as an ablative treatment in oligometastatic patients

Beatriz Debén Méndez, Marta Rodríguez Roldán, Maria Isabel Garrido Botella, Mercedes González Cantero, Macarena Teja Ubach, Alonso La Rosa, Rafael Rosel Aller, Belén Belinchón Olmeda, Lara Miralles Olivar, Luis Alberto Glaría Enriquez, Aurea De Manso De Lema, Victor Duque Santana und 2 weitere

Clinical and Translational Oncology · 20.06.2026

DOI: 10.1007/s12094-026-04462-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 20.06.2026. Verfasst von Beatriz Debén Méndez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, Hospital Universitario La Paz, Madrid, Spain. beatrizdeme@gmail.com. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extracranial oligometastatic disease, defined as up to five metastases, represents an intermediate cancer state with potential for long-term control. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment associated with high local control, limited toxicity, and the ability to delay systemic therapy. This study reports institutional outcomes of SBRT across oligometastatic scenarios. Materials and methods We retrospectively analyzed 259 patients with 401 extracranial oligometastatic lesions from solid tumors treated with SBRT between 2016 and 2022. Patients were classified according to the ESTRO–EORTC consensus as oligorecurrence, oligoprogression, or oligopersistence, and as synchronous or metachronous. The eligibility criteria included ECOG 0–1, life expectancy > 6 months, ≤ 5 treatment-naïve extracranial metastases, and no intracranial disease. Survival outcomes were estimated using the Kaplan–Meier method.

Results

After a median follow-up of 68.7 months, SBRT achieved durable local control exceeding 80% beyond 4 years across all metastatic sites, with lung and lymph node lesions showing the best outcomes. Overall disease control declined due to new metastases; however, over 40% of lesions remained progression-free at 6 years. Superior outcomes were observed in patients with genuine oligometastatic disease, de novo or synchronous presentation, and fewer treated lesions. Median overall survival (OS) was 93.8 months (95%CI 81.1–106.4) and was longer in patients with initially locoregional disease and prostate cancer.

Conclusions

In this retrospective single-center experience, SBRT achieved durable local control with acceptable toxicity in selected patients with extracranial oligometastatic disease. These findings are consistent with previously published series and support the role of SBRT as a metastasis-directed approach in carefully selected patients. Prospective studies are needed to better define prognostic subgroups and optimize patient selection.

Schlagwörter

Stichwörter der Autor:innen

Local controlOligometastatic diseaseSBRTSurvival

Autor:innen und Institutionen

  • Radiation Oncology, Hospital Universitario La Paz, Madrid, Spain. beatrizdeme@gmail.com.
  • Radiation Oncology, Hospital Universitario La Paz, Madrid, Spain.
  • Radiation Oncology, Centro de Protonterapia Quironsalud, Madrid, Spain.
  • Radiation Oncology, Hospital Central de La Defensa Gómez Ulla, Madrid, Spain.
  • Hospital General Universitario Gregorio Marañón, Hospital General Universitario Gregorio Marañón, MADRID, España.
  • Hospital Universitario de La Princesa, Hospital Universitario de La Princesa, MADRID, España.

Zitieren

APA

Debén Méndez, B., Rodríguez Roldán, M., Garrido Botella, M. I., González Cantero, M., Teja Ubach, M., La Rosa, A., Rosel Aller, R., Belinchón Olmeda, B., Miralles Olivar, L., Enriquez, L. A. G., De Manso De Lema, A., Duque Santana, V., Díez Sebastián, J., & Gonzalez Del Portillo, E. (2026). The role of SBRT as an ablative treatment in oligometastatic patients. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04462-x

Vancouver

Debén Méndez B, Rodríguez Roldán M, Garrido Botella MI, González Cantero M, Teja Ubach M, La Rosa A, et al. The role of SBRT as an ablative treatment in oligometastatic patients. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04462-x

BibTeX
@article{DebnMndez2026,
  author = {Debén Méndez, Beatriz and Rodríguez Roldán, Marta and Garrido Botella, Maria Isabel and González Cantero, Mercedes and Teja Ubach, Macarena and La Rosa, Alonso and Rosel Aller, Rafael and Belinchón Olmeda, Belén and Miralles Olivar, Lara and Enriquez, Luis Alberto Glaría and De Manso De Lema, Aurea and Duque Santana, Victor and Díez Sebastián, Jesús and Gonzalez Del Portillo, Elisabet},
  title = {The role of SBRT as an ablative treatment in oligometastatic patients},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04462-x}
}
Kostenlos starten →